Huang Le-Tian, Wang Jia-He
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Family Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Front Med (Lausanne). 2021 Oct 25;8:739251. doi: 10.3389/fmed.2021.739251. eCollection 2021.
Sarcopenia, characterized by the excessive loss of skeletal muscle mass, strength, and function, is associated with the overall poor muscle performance status of the elderly, and occurs more frequently in those with chronic diseases. The causes of sarcopenia are multifactorial due to the inherent relationship between muscles and molecular mechanisms, such as mitochondrial function, inflammatory pathways, and circulating hormones. Age-related changes in sex steroid hormone concentrations, including testosterone, estrogen, progesterone, and their precursors and derivatives, are an important aspect of the pathogenesis of sarcopenia. In this review, we provide an understanding of the treatment of sarcopenia through the regulation of sex steroid hormones. The potential benefits and future research emphasis of each sex steroid hormone therapeutic intervention (testosterone, SARMs, estrogen, SERMs, DHEA, and progesterone) for sarcopenia are discussed. Enhanced understanding of the role of sex steroid hormones in the treatment for sarcopenia could lead to the development of hormone therapeutic approaches in combination with specific exercise and nutrition regimens.
肌肉减少症的特征是骨骼肌质量、力量和功能过度丧失,与老年人整体肌肉功能不佳有关,且在患有慢性疾病的人群中更常见。由于肌肉与分子机制(如线粒体功能、炎症途径和循环激素)之间存在内在关系,肌肉减少症的病因是多因素的。包括睾酮、雌激素、孕酮及其前体和衍生物在内的性类固醇激素浓度的年龄相关变化是肌肉减少症发病机制的一个重要方面。在本综述中,我们阐述了通过调节性类固醇激素来治疗肌肉减少症的相关内容。讨论了每种性类固醇激素治疗干预(睾酮、选择性雄激素受体调节剂、雌激素、选择性雌激素受体调节剂、脱氢表雄酮和孕酮)对肌肉减少症的潜在益处和未来研究重点。加强对性类固醇激素在肌肉减少症治疗中作用的理解可能会促使开发出与特定运动和营养方案相结合的激素治疗方法。